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Abstracts
Procalcitonin is a widely used marker for the evaluation of infection and sepsis and to guide antibiotic therapy.
During the last decade, several studies evaluated its role and diagnostic performance as a surrogate marker for
the identification of Candida spp. in suspected invasive candidiasis. A low serum level and a favorable negative
predictive value are the main findings for procalcitonin in this setting. The aim of this report is to provide an
updated brief summary of the evidence supporting the use of PCT for the management of invasive candidiasis.
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We read with interest the comprehensive review by
Vijayan et al. about the role of procalcitonin (PCT)
as a marker of sepsis and guide for antibiotic ther-
apy [1]. However, we believe that another important
role of PCT should be emphasized in light of recent
literature, namely its usefulness in suspected invasive
candidiasis (IC).
IC is a frequent cause of infection and sepsis in critic-
ally ill patients and is characterized by high morbidity,
mortality, and costs [2–4]. The outcome of patients with
IC seems to be associated with timing of antifungal
treatment initiation [2, 5]. However, the turnaround time
to the microbiological diagnosis of IC is long, ranging
from 3 to 7 days [3]. Therefore, clinicians should often
prescribe antifungals before definitive microbiological
isolation of Candida spp. [6]. In fact, untargeted antifun-
gal treatment is frequently used in clinical practice with
high associated costs and potential risk of resistance [6].
In this regard, desirable features of a marker might be
the ability to help in confirming or excluding IC when
suspected and to differentiate between bacterial and fun-
gal infection/sepsis in order to optimize antimicrobial
treatment with a favorable cost-benefit balance.
In 2006, Charles et al. published a retrospective
study enrolling 50 nonsurgical septic patients with
positive blood cultures, 35 with bacteremia and 15
with candidemia [7]. They found a significantly lower
PCT level in patients with candidemia (median 0.65 ng/
ml) compared to those with bacteremia (median 9.75 ng/
ml). PCT level higher than 5.5 ng/ml demonstrated a
100% negative predictive value (NPV) and 65% positive
predictive value (PPV) for sepsis caused by Candida spp.
Martini et al. performed a prospective study enrolling 48
critically ill surgical patients with sepsis and risk of fungal
infection [8]. PCT levels were lower in patients with can-
didemia (median 0.71 [IQR 0.5–1.1]) than in those with
bacteremia (median 12.9 [IQR 2.6–81.2]). Recently,
Cortegiani et al. performed a retrospective study evalu-
ating 260 diagnostic episodes from 182 patients (60%
surgical) [9]. The aim of this study was to assess the
PCT level in septic patients with Candida, bacterial or
mixed bloodstream infection (BSI) evaluated with blood
culture (BC), and a polymerase chain reaction (PCR)
test. A significantly lower level of PCT was found in
Candida BSI (median 0.99 ng/ml [IQR 0.86–1.34]) than
in BSI caused by bacteria (median 16.7 ng/ml [IQR
7.52–50.2]) or in mixed BSI (median 4.76 ng/ml [IQR
2.98–6.08]). Consensual results were found for PCR
results. A cut-off of ≤ 6.08 ng/ml for PCT yielded a sen-
sitivity of 86.8%, a specificity of 87.6%, a PPV of 63.9%,
and a NPV of 96.3%. Interestingly, more subsequent
episodes of BSI were due to Candida compared to the
first ones. It is known that subsequent episode of noso-
comial infections is often characterized by an impaired
(hypoergic) immunity and Candida spp. infections are
often involved [6]. Authors speculated that this might
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have been one of the reasons explaining the lower level of
PCT in patients with Candida BSI, stressing a link be-
tween the low activation of the immunity, isolation of
Candida in blood, and low PCT level [9]. Very recently,
Pieralli et al. performed a retrospective case-control study
enrolling 64 septic patients with candidemia and 128 sep-
tic patients with bacteremia admitted in 3 internal medi-
cine units [10]. Again, PCT levels were lower in patients
with candidemia (median 0.73 ng/ml [IQR 0.26–1.85])
compared to those in patients with bacteremia (median
4.48 ng/ml [IQR 1.10–18.26]). PCT higher than 2.5 ng/ml
had a NPV of 98.3% with an area under the curve (AUC)
of 0.76 (0.68–0.84%) for identification of Candida spp. in
blood. Lastly, the diagnostic performance of PCT was
evaluated in association to (1-3)-beta-D-glucan (BDG),
one of the widely used surrogate markers for fungal infec-
tion. Giacobbe et al. performed a retrospective study en-
rolling 166 patients from 3 intensive care units (ICUs), 73
with candidemia and 93 with bacteremia (almost 30%
surgical and 60% medical) [11]. Patients with candidemia
had lower PCT value (median 0.76 vs 4.32 ng/ml) than
those with bacteremia. Authors evaluated together the
diagnostic performance of BDG and PCT using a com-
monly recognized cut-off value of BDG for Candida
identification (≥ 80 pg/ml) and the rounded best cut-off
calculated in their population for PCT in candidemia
(2 ng/ml). When both markers indicated candidemia, they
showed higher PPV (96%) compared to 79 and 66% for
BDG and PCT. When both indicated bacteremia, their
NPV was similar to that of BDG alone (95 vs 93%).
Although several studies demonstrated the correlation
between a low PCT level (< 2 ng/ml) and Candida infec-
tion and high NPV of PCT for Candida isolation, its role
in management of antifungal treatment is far from estab-
lished mainly because of the limitations in study design of
supporting literature. A recently published research agenda
on invasive fungal infections reported the “Utilization of
PCT to guide treatment initiation and duration” as one of
the ten priority for future trials in the field [12]. Mean-
while, clinicians might evaluate a PCT level in an infected/
septic patient with risk factors for invasive candidiasis as
one of the element to assess the probability of subsequent
Candida isolation.
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